DAYTON, N.J. — Aurobindo Pharma Ltd. has received approval from the Food and Drug Administration for olopatadine hydrochloride ophthalmic solution 0.1%.

Aurobindo said its olopatadine HCl ophthalmic solution product is a generic version of Patanol ophthalmic solution/drops from Alcon, a Novartis company.

Olopatadine hydrochloride ophthalmic solution 0.1% is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

For the 12 months through October, the medication totaled U.S. sales of $234.5 million, according to IMS Health data reported by Aurobindo.